Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Liabilities (2017 - 2025)

Serina Therapeutics (SER) has disclosed Total Liabilities for 9 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 12.42% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, up 12.42% year-over-year, with the annual reading at $7.0 million for FY2025, 12.42% up from the prior year.
  • Total Liabilities hit $7.0 million in Q4 2025 for Serina Therapeutics, down from $10.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $34.6 million in Q2 2023 to a low of $3.9 million in Q3 2023.
  • Historically, Total Liabilities has averaged $14.6 million across 5 years, with a median of $13.4 million in 2021.
  • Biggest five-year swings in Total Liabilities: plummeted 77.29% in 2023 and later skyrocketed 445.62% in 2024.
  • Year by year, Total Liabilities stood at $15.0 million in 2021, then skyrocketed by 36.78% to $20.6 million in 2022, then plummeted by 76.37% to $4.9 million in 2023, then increased by 27.95% to $6.2 million in 2024, then rose by 12.42% to $7.0 million in 2025.
  • Business Quant data shows Total Liabilities for SER at $7.0 million in Q4 2025, $10.8 million in Q3 2025, and $7.3 million in Q2 2025.